Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (NYSE:PFE) reported Phase 3 TALAPRO-3 results showing TALZENNA plus XTANDI cut the risk of radiographic progression or death by 52% vs placebo plus XTANDI in HRR-mutated metastatic castration-sensitive prostate cancer (HR=0.48; p<0.0001).
Estimated three-year rPFS was 77% vs 56%, with median rPFS not reached vs 46 months. Benefits appeared consistent across BRCA and non-BRCA subgroups. Overall survival trends favored the combination (HR=0.77; p=0.09). Safety aligned with known profiles; anemia (grade ≥3) occurred in 51% vs 3% of patients.
Pfizer (NYSE:PFE) reported seven-year Phase 3 CROWN data for LORBRENA in previously untreated ALK-positive advanced NSCLC, comparing it with XALKORI.
According to Pfizer, 55% of LORBRENA patients were alive without disease progression at seven years versus 3% on XALKORI, and median progression-free survival and intracranial progression were not reached.
Pfizer (NYSE:PFE) and Innovent Biologics (01801.HK) announced a global licensing and collaboration deal to develop 12 early-stage oncology medicines, including ADCs and multi-specific antibodies.
Innovent leads development through Phase 1, then Pfizer takes over global development. Innovent receives a $650 million upfront payment, up to $9.85 billion in potential milestones, plus double-digit royalties and shared profits on co-developed programs in the U.S. and Europe. Closing is expected in Q3, subject to regulatory approvals.
Pfizer (NYSE:PFE) will host a webcast of a discussion with Chairman and CEO Albert Bourla at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 2:00 p.m. EDT. The live webcast, transcript and replay will be available via Pfizer’s investor website.
Pfizer (NYSE:PFE) reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine 25vPnC (PF-07872412) in infants versus PREVNAR 20.
25vPnC showed 8.8-fold and ~15-fold higher serotype 3 immunogenicity after Doses 3 and 4, a safety profile consistent with existing vaccines, and potential coverage of ~90% of disease-causing serotypes, supporting initiation of a pivotal pediatric Phase 3 program and advancement of a 35-valent adult candidate.
Astellas (NYSE:PFE) will present 10 oncology-related abstracts at the ASCO 2026 meeting, including two oral presentations, covering urothelial carcinoma, prostate cancer, women’s health and pipeline programs.
Data span long-term outcomes, quality of life, subgroup analyses, and a trial-in-progress of fezolinetant and TROP2-targeted ADC ASP2998.
Pfizer (NYSE:PFE) received European Commission approval to expand HYMPAVZI (marstacimab) for adults and adolescents ≥12 years with hemophilia A or B with inhibitors, weighing ≥35 kg.
Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy, with sustained benefit and a once-weekly subcutaneous regimen.
Pfizer (NYSE: PFE) reported Q1 2026 revenue of $14.5 billion (2% operational growth) and reaffirmed full-year 2026 guidance: revenues $59.5–$62.5 billion and adjusted diluted EPS $2.80–$3.00. Reported diluted EPS was $0.47; adjusted diluted EPS was $0.75. Launched and acquired products grew 22% operationally. Pipeline momentum includes positive Phase 3 and mid-stage readouts and the company is on track to start ~20 key pivotal studies in 2026. Q1 capital deployment: $2.5B R&D, ~$110M business development, $2.4B dividends; no repurchases in 2026 planned.
Pfizer (NYSE: PFE) announced that the Phase 3 MagnetisMM-5 trial of ELREXFIO (elranatamab) met its primary endpoint at an interim analysis on April 29, 2026, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus daratumumab+pomalidomide+dexamethasone (DPd).
Safety was consistent with ELREXFIO’s known profile with no new safety signals. Overall survival remains immature and the trial is ongoing; detailed data will be submitted for a future medical congress and discussed with global health authorities.
Pfizer (NYSE: PFE) said it reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, extending the effective U.S. patent expiry for VYNDAMAX (tafamidis) to June 1, 2031, subject to other litigation outcomes. Revenues are expected to remain relatively stable from 2028 through mid-2031. VYNDAMAX holds 75% prescription volume in the ATTR-CM market. Pfizer discontinued U.S. supply of VYNDAQEL as of Dec 31, 2025, leaving VYNDAMAX available for eligible patients.